Skip to content
Review Open access

Toward Precision Vaccinology for Mpox: Rational Antigen Design, Next-Generation Platforms, and Immune Correlates of Protection

Aug 2026 · Tropical Medicine and Infectious Disease · Vol 11, pp. 244 · 0 citations · 85 references
Medicine

TL;DR

Precision vaccinology represents a transformative strategy for developing durable, clade-specific mpox vaccines and strengthening preparedness against future orthopoxvirus outbreaks worldwide.

Abstract

Mpox has emerged as a global public health concern, highlighting the limitations of traditional vaccinia-based vaccination strategies and the urgent need for precision vaccinology approaches. Advances in structural virology and immunoinformatics have enabled the identification of conserved immunodominant antigens from both mature virion and extracellular virion forms, supporting the development of multivalent antigen combinations capable of inducing broad neutralizing antibody (nAb) responses. Emerging delivery technologies including mRNA-lipid nanoparticles, viral vectors, and self-assembling protein nanoparticles offer rapid scalability, enhanced immunogenicity, and improved safety compared with conventional live-attenuated vaccines. Addressing antigenic evolution, vaccine supply limitations, and population-specific immune variability will be crucial for optimizing vaccine effectiveness. This review synthesizes current evidence on antigen design, vaccine delivery platforms, and immunological correlates of protection to outline a framework for next-generation mpox vaccines. Precision vaccinology therefore represents a transformative strategy for developing durable, clade-specific mpox vaccines and strengthening preparedness against future orthopoxvirus outbreaks worldwide.

Read PDF

Similar papers

Review Open access Aug 2026

Rational design of M2e-based nanoparticle vaccines for universal influenza a protection.

The 'ideal archetype' of a universal vaccine including M2e will be defined, and a review of the current preclinical nanoparticle based M2e vaccine will be provided, described, and analyzed.

Louis Bourlon, J. Morlieras, P. Marche et al. · 0 citations
Open access Aug 2026

A viral-vectored multipathogen vaccine platform based on replication-competent vaccinia virus and adeno-associated virus

The feasibility of the m8Δ/AAV1 platform is demonstrated as a versatile viral-vectored multipathogen vaccine platform capable of integrating protozoan and viral antigens, providing a rationale for further preclinical optimization and clinical evaluation of next generation multipathogen vaccines targeting both endemic a...

Yuna Sato, Yutaro Yamamoto, A. Hasyim et al. · 0 citations
Review Open access 2026

A review of vaccine adjuvants in modern immunology: Mechanisms, classes, and advances in next generation vaccine design

Vaccines are biological preparations that stimulate the immune system to prevent infectious disease without causing illness. By delivering weakened or inactivated pathogens, purified antigens, or genetic material encoding specific proteins, vaccines induce antibody production and generate memory B and T cells, enabling...

M. Nwigube, C. Eya, C. C. Agu et al. · 0 citations
Open access Sep 2026

Proteome-Wide Reverse Vaccinology and Immunoinformatics-Guided Design of a Multi-Epitope Vaccine Against Legionella pneumophila

Legionella pneumophila is a Gram-negative opportunistic pathogen responsible for Legionnaires’ disease, a severe form of atypical pneumonia associated with high morbidity and mortality, particularly in immunocompromised individuals. Despite its growing global burden and the persistence of environmental reservoirs, no l...

Lokesh Thangamani, Tong Lian · 0 citations
Open access Aug 2026

Leveraging immunoinformatic techniques for the development of a multi-epitope subunit vaccine targeting virulence-associated proteins of Mycobacterium tuberculosis

A multi-epitope subunit vaccine (MESV) candidate using immunoinformatic approaches that targets five virulence-associated proteins and may elicit potent humoral and cellular immune responses against M. tuberculosis are viable options warranting further experimental validation.

Swagat Ranjan Maharana, S. Khan, Kiran Mahapatra et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.